- Target disease: VL
- Main partners (since project start): AbbVie, USA; Anacor Pharmaceuticals Inc, USA; AstraZeneca, UK; Drug Discovery Unit, University of Dundee, UK; Epichem, Australia; Eskitis Institute for Cell and Molecular Therapies, Griffith Institute for Drug Discovery, Griffith University, Australia; Eisai Co Ltd, Japan; Institut Pasteur Korea, South Korea; Fundaçao de Apoio Universidade Federale de Sao Paolo, Brazil; Centre for Drug Candidate Optimization, Monash University, Australia; Griffith University, Australia; GlaxoSmithKline, Tres Cantos, Spain; Laboratory of Microbiology, Parasitology and Hygiene, University ofAntwerp, Belgium; London School of Hygiene & Tropical Medicine, UK; Merck, USA; Sanofi, France; Shionogi & Co Ltd, Japan; Sandexis, UK; Takeda Pharmaceutical Company Ltd, Japan; TCG Lifesciences, India; The Swiss Tropical and Public Health Institute, Switzerland; Universidade Estadual de Campinas, UNICAMP, Brazil; WuXi AppTech, China.
- Project start: Ongoing
- Funding (since project start): Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW).
Hit-to-lead is a dynamic phase in the drug discovery cascade in which small molecule hits from high throughput screens are evaluated and undergo optimization to identify promising lead compounds.
This process of hit-to-lead optimization is ongoing with multiple series from several pharmaceutical companies.If promising activity can be demonstrated in pre-clinical models of leishmaniasis, the series will be advanced into full lead optimization.
A number of pharmacokinetic and pharmacodynamic studies have been conducted in animal models of VL using existing and experimental drugs to build improved PK/PD models and ameliorate the translation of new drugs from discovery into clinical studies.
Last update: March 2018